Does Cadrenal Therapeutics Inc (NASDAQ:CVKD) Look Expensive At $0.91? Here’s How To Know.

In last trading session, Cadrenal Therapeutics Inc (NASDAQ:CVKD) saw 1.69 million shares changing hands with its beta currently measuring 2.25. Company’s recent per share price level of $0.91 trading at -$0.22 or -19.47% at ring of the bell on the day assigns it a market valuation of $11.85M. That closing price of CVKD’s stock is at a discount of -245.05% from its 52-week high price of $3.14 and is indicating a premium of 56.04% from its 52-week low price of $0.40. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.02 million shares which gives us an average trading volume of 289.27K if we extend that period to 3-months.

Cadrenal Therapeutics Inc (NASDAQ:CVKD) trade information

Upright in the red during last session for losing -19.47%, in the last five days CVKD remained trading in the red while hitting it’s week-highest on Friday, 02/02/24 when the stock touched $0.91 price level, adding 43.12% to its value on the day. Cadrenal Therapeutics Inc’s shares saw a change of 22.99% in year-to-date performance and have moved -35.46% in past 5-day. Cadrenal Therapeutics Inc (NASDAQ:CVKD) showed a performance of 39.02% in past 30-days. Number of shares sold short was 40210.0 shares which calculate 0.28 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

CVKD Dividends

Cadrenal Therapeutics Inc is more likely to be releasing its next quarterly report in March and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Cadrenal Therapeutics Inc (NASDAQ:CVKD)’s Major holders

Insiders are in possession of 58.47% of company’s total shares while institution are holding 8.49 percent of that, with stock having share float percentage of 20.45%. Investors also watch the number of corporate investors in a company very closely, which is 8.49% institutions for Cadrenal Therapeutics Inc that are currently holding shares of the company.

On Key

Related Posts